News from all angles
(MedPage Today) -- An analysis of patients with metastatic castration-resistant prostate cancer presented at the European Society for Medical Oncology (ESMO) congress found no statistically significa…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network